HK40583A - Nifedipine-containing solid preparation composition - Google Patents

Nifedipine-containing solid preparation composition

Info

Publication number
HK40583A
HK40583A HK405/83A HK40583A HK40583A HK 40583 A HK40583 A HK 40583A HK 405/83 A HK405/83 A HK 405/83A HK 40583 A HK40583 A HK 40583A HK 40583 A HK40583 A HK 40583A
Authority
HK
Hong Kong
Prior art keywords
nifedipine
substance
mixture
cellulose
containing solid
Prior art date
Application number
HK405/83A
Other languages
English (en)
Inventor
Kawata Hiroitsu
Ohmura Tadayoshi
Yano Katsuhiko
Matsumura Mikio
Higuchi Saburo
Soeishi Yoshiaki
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26408243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK40583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP6703977A external-priority patent/JPS542316A/ja
Priority claimed from JP8437277A external-priority patent/JPS5420127A/ja
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of HK40583A publication Critical patent/HK40583A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
HK405/83A 1977-06-07 1983-10-13 Nifedipine-containing solid preparation composition HK40583A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6703977A JPS542316A (en) 1977-06-07 1977-06-07 Solid pharmaceutical composition containing nifedipene
JP8437277A JPS5420127A (en) 1977-07-14 1977-07-14 Solid nifedipine preparaton

Publications (1)

Publication Number Publication Date
HK40583A true HK40583A (en) 1983-10-21

Family

ID=26408243

Family Applications (1)

Application Number Title Priority Date Filing Date
HK405/83A HK40583A (en) 1977-06-07 1983-10-13 Nifedipine-containing solid preparation composition

Country Status (5)

Country Link
US (1) US4412986A (enExample)
DE (1) DE2822882A1 (enExample)
GB (1) GB1579818A (enExample)
HK (1) HK40583A (enExample)
MY (1) MY8400231A (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012523B2 (en) * 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
JPS5948810B2 (ja) * 1980-03-22 1984-11-29 山之内製薬株式会社 ニカルジピン持続性製剤用組成物
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5668609A (en) 1979-11-07 1981-06-09 Nippon Kayaku Co Ltd Phthalazinol preparation
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
EP0070127A3 (en) * 1981-07-10 1983-08-17 Beecham Group Plc Tablets
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
USRE33963E (en) * 1981-10-29 1992-06-16 Bayer Aktiengesellschaft Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation
DE3142853A1 (de) * 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung
DE3381877D1 (de) * 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
DE3212736A1 (de) * 1982-04-06 1983-10-13 Bayer Ag, 5090 Leverkusen Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
ATE33348T1 (de) * 1983-11-30 1988-04-15 Siegfried Ag Coronartherapeutikum in form von weichgelatinekapseln.
ATE62414T1 (de) * 1984-01-28 1991-04-15 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
US5948769A (en) * 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
EP0159604B1 (en) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
DE3419128A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinpraeparate und verfahren zu ihrer herstellung
DE3419129A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Nifedipinpraeparate und verfahren zu ihrer herstellung
DE3419131A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
DE3419130A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Nifedipinkombinationspraeparate und verfahren zu ihrer herstellung
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
AU592065B2 (en) * 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
DE3544692A1 (de) * 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
AU597049B2 (en) * 1986-03-10 1990-05-24 Kurt Burghart Pharmaceutical preparation containing nifedipine
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
DE3682208D1 (de) * 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5051272A (en) * 1988-07-19 1991-09-24 United States Surgical Corporation Method for improving the storage stability of a polymeric article susceptible to hydrolytic degradation and resulting article
US5226912A (en) * 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
PH26518A (en) * 1987-11-11 1992-08-07 Fujisawa Pharmaceutical Co A novel pharmaceutical composition comprising exifone and water-soluble polymer
DE3829398A1 (de) * 1988-08-30 1990-03-08 Rentschler Arzneimittel Fixe arzneimittelkombination mit verzoegerter freisetzung
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
US5246104A (en) * 1989-08-01 1993-09-21 United States Surgical Corporation Molded suture retainer
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
DK0489181T3 (da) * 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
CA2056032A1 (en) * 1990-11-29 1992-05-30 Minoru Aoki Hard capsule preparation
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
GR910100193A (el) * 1991-05-03 1993-03-31 Mediventures Inc Παρασκευη φαρμακευτικων και αλλων περιβληματων με διαλυση σε στερεα κατασταση.
JP3110794B2 (ja) * 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
CA2144077C (en) * 1992-09-18 2005-05-24 Kazuhiro Sako Hydrogel-type sustained-release preparation
US5603945A (en) * 1993-02-19 1997-02-18 Takeda Chemical Industries, Ltd. Therapeutic/prophylactic agents and method of treating for urinary calculosis in pets
IS4198A (is) * 1993-08-13 1995-02-14 Somatogen, Inc Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
RU2138525C1 (ru) * 1993-10-25 1999-09-27 Байер Аг Композиция с биологической активностью и водное средство защиты растений
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
WO1996011672A1 (en) * 1994-10-13 1996-04-25 Wakamoto Pharmaceutical Co., Ltd. Lyophilized preparation providing reversibly thermogelling water-base medicinal composition
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
NZ286451A (en) * 1996-04-24 1998-04-27 Bernard Charles Sherman Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier
ATE417604T1 (de) 1996-07-08 2009-01-15 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
US6531158B1 (en) 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP3386052B2 (ja) * 2001-02-13 2003-03-10 トヨタ自動車株式会社 ポンプ装置
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
US7039078B2 (en) * 2002-09-17 2006-05-02 Nippon Telegraph And Telephone Corporation Semiconductor optical modulator and laser with optical modulator
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
MX2007004973A (es) * 2004-10-25 2007-06-14 Japan Tobacco Inc Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
EP2000152A4 (en) * 2006-03-23 2013-01-23 Shionogi & Co SOLID PREPARATION WITH IMPROVED SOLUBILITY
JP7470647B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド ジヒドロピリジン型カルシウムチャネル遮断薬医薬組成物を用いて血圧を低下させるための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862161A (en) * 1970-01-24 1975-01-21 Bayer Ag 4-pyridyl substituted 1,4-dihydropyridines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3932645A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
SU432703A3 (enExample) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
US3920823A (en) * 1972-03-06 1975-11-18 Bayer Ag Use of unsymmetrical esters of n-substituted 1,4-dihydropyridine 3,5-dicarboxylic acid as cardio-vascular agents
US3959296A (en) * 1972-06-10 1976-05-25 Bayer Aktiengesellschaft 1,4-Dihydropyridines
US3943140A (en) * 1972-09-30 1976-03-09 Bayer Aktiengesellschaft 2,3,5,6-Tetracarboxy-1,4-dihydropyridine derivatives
US3971796A (en) * 1973-07-12 1976-07-27 Bayer Aktiengesellschaft 1,4-Dihydropyridine esters
DE2400819C2 (de) 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung

Also Published As

Publication number Publication date
MY8400231A (en) 1984-12-31
US4412986A (en) 1983-11-01
DE2822882A1 (de) 1978-12-21
DE2822882C2 (enExample) 1987-06-25
GB1579818A (en) 1980-11-26

Similar Documents

Publication Publication Date Title
HK40583A (en) Nifedipine-containing solid preparation composition
ES8200557A1 (es) Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido.
IE790704L (en) Cyclosporin composition
CA2294031A1 (en) Self-emulsifying formulation for lipophilic compounds
GB8730011D0 (en) Pharmaceutical compositions
CA2158630A1 (en) Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
IE940583L (en) Topical antimicrobial pharmaceutical compositions
AR240872A1 (es) Novedosas composiciones tensioactivas con base de esteres fosforicos de derivados polioxialquenados, su procedimiento de preparacion y su aplicacion a la formulacion de materias activas.
JPS56110612A (en) Readily disintegrable and absorbable compression molded article of slightly soluble drug
CA2383036A1 (en) Solid lipid formulations
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
IE781032L (en) Pharmaceutical compositions
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
WO1999008666A3 (en) Pharmaceutical composition comprising an azateroid
IE45534L (en) Pharmaceutical compositions
ATE324103T1 (de) Arzneizubereitung mit kontrollierter freisetzung enthaltend tramadol hydrochlorid
NO157330C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive 3-metylflavon-8-karboksylsyreestere.
GB2021409A (en) Pharmaceutical composition
JPS5668619A (en) Nifedipine-containing solid composition
WO2001022969A3 (en) Vasopressin agonist formulation and process
EP0056681A3 (en) Levonantradol and n-methyllevonantradol formulations
KR900701254A (ko) 정제 가능한 제제 및 이것으로 만들어진 정제
JPS55129220A (en) Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
HUT39752A (en) Insecticide, acaricide, and nematocide compositions containing pyridyl-thiono-phosphoric acid esters as active ingredients and process for preparing the active ingredient

Legal Events

Date Code Title Description
PE Patent expired